Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(01): 09-18
DOI: 10.1055/s-0041-1727560
Viewpoint

Indian Expert Opinion on Cancer Care during COVID-19 Pandemic

Ashok K. Vaid
1   Department of Medical Oncology and Hematology, Medanta Cancer Institute, Medanta—The Medicity, Gurgaon, Haryana, India
,
Hemant Malhotra
2   Department of Medical Oncology, Sri Ram Cancer Center, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India
,
Raja Thirumalairaj
3   Department of Medical Oncology, Apollo Hospitals, Chennai, Tamil Nadu, India
,
Reena Nair
4   Department of Clinical Hematology, Tata Medical Centre, Kolkata, West Bengal, India
,
Ajay Bapna
5   Department of Medical Oncology, Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan, India
,
Senthil J. Rajappa
6   Department of Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India
,
S. P. Somashekhar
7   Department of Surgical Oncology, Manipal Comprehensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India
,
Chanchal Goswami
8   Oncology Services, Medica Institute of Breast Diseases, Medica Superspecialty Hospital, Kolkata, West Bengal, India
,
Jyoti Bajpai
9   Department of Medical Oncology, Tata Memorial Hospital/Center, Mumbai, Maharashtra, India
› Author Affiliations Source of Funding The manuscript writing was funded by Mylan Pharma-ceuticals Private Limited.
› Further Information
   Permissions and Reprints

Abstract

Coronavirus pandemic has increased human disease burden, as well as economic distress globally. Being in an immunocompromised state, patients with cancer comprise an important at-risk population for novel coronavirus disease 2019 (COVID-19) infection. It is necessary to modify individualized clinical management for every cancer patient in the context of the ongoing COVID-19 pandemic. Simultaneously, additional safety precautions for the cancer care providers are mandatory. This review will provide general recommendations in the Indian context optimizing the same.

Keywords

India - oncology management - recommendations - patient safety


Publication History

Article published online:
21 August 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 WHO coronavirus disease (COVID-19) dashboard. Available at: https://covid19.who.int/. Accessed June 12, 2020
  • 2 Ministry of Health and Family Welfare Government of India. COVID-19 Statewise status. Available at: https://www.mohfw.gov.in/. Accessed June 12, 2020
  • 3 Mehta P, Parikh P, Aggarwal S. et al. Has India met this enemy before? From an eternal optimist’s perspective: SARS-CoV-2. Indian J Med Sci 2020; 72 (01) 8-12
    CrossrefGoogle Scholar
  • 4 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21 (03) 335-337
    CrossrefPubMedGoogle Scholar
  • 5 Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at: who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed April 29, 2020
  • 6 Zhang L, Zhu F, Xie L. et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020; 31 (07) 894-901
    CrossrefPubMedGoogle Scholar
  • 7 Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and cancer: lessons from a pooled metanalysis. JCO Glob Oncol 2020; 6: 557-559
    CrossrefPubMedGoogle Scholar
  • 8 Abraham P, Aggarwal N, Babu GR. et al. Laboratory surveillance for SARS-CoV-2 in India: performance of testing & descriptive epidemiology of detected COVID-19, January 22 - April 30, 2020. Ind J Med Res 2020; 151 (05) 424-437
    CrossrefPubMedGoogle Scholar
  • 9 Lai AG, Pasea L, Banerjee A. et al. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open 2020; 10: e043828
    CrossrefPubMedGoogle Scholar
  • 10 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10/229) 1054-1062
    CrossrefPubMedGoogle Scholar
  • 11 Parikh P, Mehta P, Bansal S. et al. Protecting health-care professionals and workers (other than COVID-19 management facilities) from contamination during COVID-19 pandemic (March 26, 2020 - India).. Int J Med Sci 2020; 72 (01) 3-4
    Google Scholar
  • 12 Gundavda MK, Parikh PM. Why the use of face masks by everyone outside their homes is still mandatory during the COVID-19 pandemic. Indian J Med Sci 2020; DOI: 10.25259/IJMS_311_2020.
    CrossrefGoogle Scholar
  • 13 Parikh PM, Bapna A, Krishna MV. et al COVID-19 testing in India in comparison to the rest of the world. If Indian testing strategy was replicated in the other top 15 COVID-19 affected countries in the world, the status would be startlingly different. Indian J Med Sci 2020; 72 (02) 107-109
    CrossrefGoogle Scholar
  • 14 ESMO guideline. Cancer patient management during the COVID-19 pandemic. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic?hit=ehp. Accessed April 29, 2020
  • 15 WHO-Coronavirus disease (COVID-19) advice for the public. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public. Accessed April 29, 2020
  • 16 Al-Shamsi HO, Alhazzani W, Alhuraiji A. et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: An International Collaborative Group. Oncologist 2020; 25 (06) e936-e945
    CrossrefPubMedGoogle Scholar
  • 17 COVID-19 rapid guideline: delivery of systemic anticancer treatments. Available at: https://www.nice.org.uk/guidance/ng161. Accessed May 6, 2020
  • 18 COVID-19 rapid guideline: delivery of radiotherapy. Available at: https://www.nice.org.uk/guidance/ng162. Accessed May 6, 2020
  • 19 COVID-19 rapid guideline: hematopoietic stem cell transplantation. Available from: https://www.nice.org.uk/guidance/ng164. Accessed May 6, 2020
  • 20 Telemedicine Practice Guidelines. Available at: https://www.mohfw.gov.in/pdf/Telemedicine.pdf Accessed April 30, 2020
  • 21 World Health Organization (WHO). Infection prevention and control during health care when COVID-19 is suspected. March 19, 2020. Available at: https://www.who.int/publications/i/item/10665-331495. Accessed May 5, 2020
  • 22 American Society of Clinical Oncology. COVID-19 Provider & Practice Information. Available at: https://www.asco.org/asco-coronavirus-information/provider-practice-preparedness-covid-19. Accessed May 5, 2020
  • 23 Waterhouse DM, Harvey RD, Hurley P. et al. Early impact of covid-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology Survey. JCO Oncol Pract 2020; 16 (07) 417-421
    CrossrefPubMedGoogle Scholar
  • 24 U.S. Food and Drug Administration. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards, March 2020. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency. Accessed May 5, 2020
  • 25 Sidley Austin LLP. Considerations for Sponsors of Ongoing Clinical Trials in Light of COVID-19 (Part 1). March 31, 2020. Available at: https://www.sidley.com/en/insights/newsupdates/2020/03/covid19-considerations-for-sponsors-of-ongoing-clinical-trials-in-light-of-covid19-part1. Accessed May 5, 2020
  • 26 National Cancer Institute. General Guidance for All Trials (Both IND and Non-IND Trials). Available at: https://www.ncicirb.org/system/files/Interim_Guidance_Clinical_Trial_Activities_Affected_%20by_Novel_Coronavirus_3-13-2020_0.pdf. Accessed May 5, 2020
  • 27 Parikh PM, Mehta P, Krishna Kumar MVT. et al Clinical trials facing “serious adverse events” during the ongoing COVID-19 pandemic. Indian J Med Paediatr Oncol 2020; 41 (03) 295-298
    Article in Thieme ConnectGoogle Scholar
  • 28 Globocan 2020fact sheet: India. Available at: https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf. Accessed May 9, 2020
  • 29 ESMO management and treatment adapted recommendations in the Covid-19 era: Breast cancer. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era. Accessed April 30, 2020
  • 30 Updated IASO. Updated IASO Covid-19/Curfew Guidelines. Dated 25th March 2020. Available at: https://iasoindia.in/wp-content/uploads/2020/03/Official-IASO-COVID-19-Guidelines.pdf Accessed April 30, 2020
  • 31 Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium. Available at: https://www.nccn.org/covid-19/pdf/The_COVID-19_Pande-mic_Breast_Cancer_Consortium_Recommendations.pdf. Accessed May 8, 2019
  • 32 ESMO management and treatment adapted recommendations in the covid-19 era: lung cancer. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/lung-cancer-in-the-covid-19-era. Accessed May 8, 2019
  • 33 Short-term recommendations for non-small cell lung cancer management during the COVID-19 pandemic. Available at: https://www.nccn.org/covid-19/pdf/COVID_NSCLC.pdf Acces-sed May 3, 2020
  • 34 Percival MM, Lynch RC, Halpern AB. et al. Considerations for managing patients with hematologic malignancy during the COVID-19 pandemic: the Seattle Strategy. JCO Oncol Pract 2020; 16 (09) 571-578
    CrossrefPubMedGoogle Scholar
  • 35 Yahalom J, Dabaja BS, Ricardi U. et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood 2020; 135 (21) 1829-1832
    CrossrefPubMedGoogle Scholar
  • 36 Lou E, Beg S, Bergsland E. et al. Modifying practices in GI Oncology in the face of COVID-19: Recommendations from expert oncologists on minimizing patient risk. JCO Oncol Pract 2020; 16 (07) 383-388
    CrossrefPubMedGoogle Scholar
  • 37 ESMO management and treatment adapted recommendations in the covid-19 era: hepatocellular carcinoma (HCC). Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/gastrointestinal-cancers-hepatocellular-carcinoma-hcc-in-the-covid-19-era. Accessed April 30, 2020
  • 38 ESMO management and treatment adapted recommendations in the covid-19 era: sarcomas. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/sarcomas-in-the-covid-19-era. Accessed April 30, 2020
  • 39 ESMO management and treatment adapted recommendations in the covid-19 era: melanomas. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/melanoma-in-the-covid-19-era. Accessed April 30, 2020
  • 40 ESMO management and treatment adapted recommendations in the covid-19 era: cervical cancer. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/gynaecological-malignancies-cervical-cancer-in-the-covid-19-era. Accessed April 30, 2020
  • 41 ESMO management and treatment adapted recommendations in the covid-19 era: epithelial ovarian cancer. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/gynaecological-malignancies-epithelial-ovarian-cancer-in-the-covid-19-era. Accessed April 30, 2020
  • 42 Principles for management of colorectal cancer patients during the COVID-19 pandemic. Available at https://www.nccn.org/covid-19/pdf/Colorectal%20COVID-19.pdf. Accessed April 30, 2020
  • 43 Management of prostate cancer during the COVID-19 pandemic. Available from: https://www.nccn.org/covid-19/pdf/NCCN_PCa_COVID_guidelines.pdf. Accessed May 10, 2020
  • 44 ESMO management and treatment adapted recommendations in the COVID-19 era: prostate cancer. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/genitourinary-cancers-prostate-cancer-in-the-covid-19-era . Accessed May 10, 2020
  • 45 Gundavda KK, Parikh PM. Convalescent plasma therapy for COVID-19 still has the potential to save lives - The ICMR PLACID study dissected. Int J Mol Immuno Oncol 2021; 6 (01) 47-49
    CrossrefGoogle Scholar
  • 46 Budhiraja S, Dewan A, Aggarwal R. et al. Effectiveness of convalescent plasma therapy in Indian patients with COVID-19. Blood Cells Mol Dis 2020; 88: 102548
    CrossrefPubMedGoogle Scholar